Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis

This study has been terminated.
(SB-656933 is no longer being developed for ulcerative colitis.)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 5, 2008
Last updated: January 31, 2017
Last verified: January 2017
This study will involve the use of a new compound, SB-656933. Accumulation of inflammatory white blood cells (mostly polymorphonuclear neutrophils)in the gut (colon) may be contributing to the pathology of ulcerative colitis. It has been shown that SB-656933 reduces polymorphonuclear neutrophils (PMN) accumulation in pre-clinical models of colitis. 99m-Tc-HMPAO scintigraphy is a imaging technique which will be used in this study to observe the effect of SB656933 on the migration of PMN to inflamed tissue.

Condition Intervention Phase
Colitis, Ulcerative
Drug: SB-656933
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Changes from baseline to after 1 and 7 days treatment with a daily dose of SB-656933-AAA in 99mTc-HMPAO labelled leukocyte Single Photon Emission Computerized Tomography (SPECT) Scintigraphic Activity Scores (SAS). [ Time Frame: 7 Days ]

Secondary Outcome Measures:
  • Safety and tolerability of SB-656933-AAA,amount of medicine in blood,changes from baseline to after treatment in faecal calprotectin and in induced CD11b levels in a whole blood assay,Correlation between SB-656933 blood level and 99mTc-HMPAO SPECT SAS [ Time Frame: 7 Days ]

Enrollment: 3
Study Start Date: January 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 7 Days Repeat Dose Drug: SB-656933
7 days repeat dose
Other Name: SB656933


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • A history of ulcerative colitis for at least 3 months
  • moderately active UC, either stable on medications or in a flare of the disease
  • Mayo endoscopic score of 2 or 3 within 2 days of dosing.
  • Male or female between 18 and 65 years of age
  • Women of child bearing potential must use an effective method of contraception.
  • Male subjects must agree to use one of the specified contraception method,
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal at study start.
  • Signed written informed consent
  • QTcB or QTcF < 450msec at screening

Exclusion criteria:

  • The subject has a positive pre-study drug/alcohol screen.
  • A positive test for HIV, hepatitis B or C.
  • History of regular alcohol consumption within 6 months of the study
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days or 5 half-lives prior to the first dose of study medication
  • Known allergies
  • recent participation in another trial
  • recent blood donation
  • Pregnant or lactating females
  • unwillingness or inability to follow study procedures
  • consumption of red wine, seville oranges, grapefruit or grapefruit juice in last 7 seven day before study start.
  • Mild UC, Mayo endoscopic score of 0 or 1.
  • Toxic megacolon or perforation on plain abdominal Xray.
  • Crohn's Disease, indeterminate colitis, bleeding disorders, or active ulcer disease.
  • Previous colonic surgery.
  • Current or recurrent disease, other than UC, that could affect the action, absorption or disposition of the study medication, or clinical or laboratory assessments.
  • Absolute neutrophil count below 2.0x109/L.
  • A positive culture for enteric pathogens that is clinically significant, presence of clostridium difficile toxin, or with ova and parasites detected by microscopy, or has a clinical suspicion of an infectious disease of the bowel.
  • Symptomatic GI stricture within 6 months of screening or obstructive symptoms within 3 months of screening.
  • Likely to require abdominal surgery within the study period.
  • Congenital or acquired immunodeficiency, including any immunologic diseases with gastrointestinal involvement except for UC.
  • Ongoing neoplastic disease of the bowel.
  • History of prostatitis, epididymitis, epididymal cysts, structural abnormalities or testicular cancer.
  • Subjects with abnormalities of the renal tract, renal stones or history of recurrent urinary tract infections (UTI.s).
  • Subjects with any history of autoimmune hepatitis or sclerosing cholangitis. Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden.
  • Blood pressure persistently ≥ 140/90 mmHg at screening
  • Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, autoimmune, renal, pulmonary, hepatic, endocrine, metabolic, haematological, or neurological condition).
  • Clinically significant hepatic impairment(Evidence of cirrhosis, Clinical episodes of jaundice)
  • Current evidence of, or has been treated for a malignancy within the past 5 years.
  • BMI <18 kg.m2 or >35 kg/m2
  • Clinically significant renal laboratory values.
  • Has not discontinued any prohibited concomitant medication prior to the screening visit or within the protocol-specified time period.
  • Has not remained on a stable dose of any permitted concomitant medication(s) for the protocol-specified time period preceding the Screening Visit.
  • history of substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00748410

GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Study Data/Documents: Dataset Specification  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register
Statistical Analysis Plan  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register
Study Protocol  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the site
Identifier: CUC111342
For additional information about this study please refer to the GSK Clinical Study Register

Responsible Party: GlaxoSmithKline Identifier: NCT00748410     History of Changes
Other Study ID Numbers: CUC111342
Study First Received: September 5, 2008
Last Updated: January 31, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through following the timelines and process described on this site.

Keywords provided by GlaxoSmithKline:
Ulcerative colitis
99mTc-HMPAO-labelled leukocyte scintigraphy

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases processed this record on April 27, 2017